Upstream Bio, Inc. (UPB) shares tumbled 51.55 percent, falling $13.48 to $14.33 on Wednesday, even after the company announced positive top-line results from its Phase 2 VALIANT clinical trial evaluating verekitug in adults with severe asthma.
The clinical-stage biotechnology company said the study assessed the safety and efficacy of verekitug, an antagonist targeting the receptor for thymic stromal lymphopoietin, in patients with severe respiratory disease.
The stock is currently trading at $14.98, down from a previous close of $27.81. Shares opened at $19.00 and have traded between $15.30 and $20.00 during the session on the Nasdaq. The last bid was $14.39 for 200 shares, while the ask stood at $19.66 for 200 shares. Trading volume reached about 2.79 million shares, significantly above the average volume of about 0.59 million.
Upstream Bio shares have traded within a 52-week range of $5.14 to $33.68.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.